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 Developing a novel NFOH-loaded nanostructured lipid carrier for oral administration to 
treat leishmaniasis, using a design space approach 
 Selecting liquid and solid lipids using new Crystal 16TM and differential scanning 
calorimetry, respectively 
 High-pressure homogenization used for the preparation of formulations 
 Determination of NFOH in plasma rat after oral administration 
 
Abstract 
Hydroxymethilnitrofurazone (NFOH) is a nitrofurazone derivative, and has potential use in 
treating leishmaniasis. However, due to low solubility and bioavailability, NFOH has failed in in 
vivo tests. Nanostructured lipid carrier (NLC) is an alternative to overcome these limitations, by 
improving pharmacokinetics and modifying drug delivery. This work is focused on developing a 
novel NFOH-loaded NLC (NLC-NFOH) for oral administration to treat leishmaniasis, using a 
design space approach. The solubility of NFOH in different liquid lipids (LL) was performed in a 
Technobis Crystal 16TM (Technobis, Alkmaar, Netherlands) at 80°C, 700 rpm for 1h. Aiming to 
improve NFOH solubility, 0.2g of phosphatidylcholine from soybean (Lipoid® S100) was added 
to the LL. The solubility of NFOH in solid lipid (SL) was performed by microscopy and DSC 
analysis. High-pressure homogenization, at 600 bar, five consecutive cycles, and a D-Optimal 
mixture statistical design was applied to develop NLC formulation. NLC-NFOH (2.8 mg/kg) was 
administered to one healthy male Wistar rat (341g) by gavage. Blood from the carotid vein was 
collected and the sample was analyzed by HPLC. Mygliol® 840 was selected as LL and 
Gelucire® 50/13 and Precirol® ATO 5 as SL to solubilize NFOH. The optimized NLC-NFOH 
presented z-average of 198.6 ± 5.4 nm, PDI of 0.11 ± 0.01 and zeta potential of -13.7 ± 0.7 mV. 
The plasma concentration of NFOH after 5h of oral administration was 0.22 µg/mL. A rational 
approach allowed for developing the first NLC-NFOH. Moreover, NLC-NFOH showed the 
potential development of a new oral medicine for treating leishmaniasis. 
Keywords: Leishmaniasis; Nanoparticle(s); Drug delivery system(s), Lipid-based formulation(s); 
Nanostructured lipid carrier; Hydroxymethylnitrofurazone 
 
Introduction 
Leishmaniasis is a neglected tropical disease, in which the parasite infects 
macrophages in liver, spleen, bone marrow, and lymph nodes [1]. Currently, the first-line 
treatment for leishmaniasis is pentavalent antimonials administered via parenteral: meglumine 
antimoniate (Glucantime®, Sanofi Aventis, 81 mg/mL, solution) and sodium stibogluconate 
(PentostamTM, Glaxo Smith Kline, 100 mg/mL, solution for injection). Other alternative drugs 
may include pentamidine and amphotericin B, also administered parenterally [2]. However, they 
require the administration of high and repeated doses and at least 20 days of treatment and 
hospitalization [1,3]. Additionally, these medicines show side effects such as pancreatitis, 
cardiotoxicity, nephrotoxicity and hepatotoxicity and induction of drug-resistant strains [4]. 
Hydroxymethylnitrofural (NFOH) (Figure 1A) has been a promising alternative for 
treating leishmaniasis. Chung et al [5] first obtained this compound, using a molecular 
modification of nitrofurazone (NF) (Figure 1B), a topical antimicrobial agent. NFOH showed high 
activity in cultures of the infected cell of Trypanosoma cruzi and lower toxicity compared to NF. 
It also shows activity against L. amazonensis, which was confirmed by in vitro test using NFOH- 
poly n-butyl cyanoacrylate (PBCA) nanoparticles [6]. Despite this promising efficacy, the low 
water solubility of NFOH has limited its therapeutic use [6]. 
 
Figure 1. Chemical structure of hydroxymethylnitrofural (A) and nitrofurazone (B) [5].  
 
In search of new approaches to overcome this limitation, nanostructured lipid systems 
have promising qualities. They have a distinctive record in improving pharmacokinetics,  
modifying drug delivery, and can be used to target the drug at a specific site [3,7]. Thus, it is 
possible to increase efficacy, reduce toxicity, and reduce the frequency and duration of 
treatment [8]. Also, nanostructured preparations can increase the time of drug circulation in the 
body and encapsulated lipophilic molecules [9]. Among the alternatives there are nanoemulsion 
(NE), solid lipid nanoparticles (SLN), and nanostructured lipid carriers (NLC), the second 
generation of solid lipid nanoparticles. 
NLC is comprised of colloidal particles that present a matrix composed of a binary 
mixture of solid lipid and liquid lipid giving rise to a less ordered structure, solid at room and 
body temperature [10]. This feature allows higher encapsulation efficiency compared to 
conventional SLN [11]. NLC can be prepared using high pressure homogenization, a scale up 
feasible technology [12]. NLC has many advantages, such as low production cost, no need for 
organic solvents, and high stability. Additionally, Monteiro et al. showed that NLC loaded with 
buparvaquone improved the in vitro activity against Leishmania infantum [13]. Similar results 
were revealed using amphotericin B-NLC and cedrol-NLC. These nanosystems show better 
activity against Leishmania sp after oral administration in an animal model compared to the free 
drugs [14,15].  
However, a systematic rational approach is required in developing NLC to select its 
proper components and their concentration. The lipids with higher drug solubility can increase 
the drug loading, encapsulation efficiency and enhance the stability of nanoparticles [16,17]. 
Thus, this task is a critical part of the formulation development. 
Moreover, the concept of space design in pharmaceutical development has been 
considered an important stage of quality by design. Design space offers quality assurance and 
process understanding by a multivariate combination and interaction of input variables [18,19]. It 
can be achieved using design of experiments (DoE). The applicability of DoE has increased due 
to its ease in overcoming limitations and time-consuming methodologies [12,18,20]. Therefore, 
this work is focused on developing a novel NFOH-loaded NLC for oral administration to treat 
leishmaniasis, using a design space approach. 
 
Material and Method 
Material 
Hydroxymethylnitrofurazone was synthesized as previously described by Chung et al. 
(2003). Hydrogenated palm oil (Softisan® 154 and Dynasan® P60), tristearin (Dynasan® 118) 
and saturated fatty acid triglycerides (Witepsol® E85) were kindly donated by IOI Oleo Chemical 
(Germany). Lauroyl polyoxyl-32 glycerides (Gelucire® 44/14), stearoyl polyoxyl-32 glycerides 
(Gelucire® 50/13), glyceryl dibehenate (Compritol® 888) and glyceryl distearate (Precirol® ATO 
5) were kindly donated by Gattefossé (France). Oleic acid, glyceryl caprylate/caprate (Capmul® 
MCM EP), glyceryl tricaprylate/tricaprate (Captex® 300 EP/NF) and triglycerides of oleic acid 
(Captex® GTO) were kindly donated by Abitec (USA). Super refined cottonseed, safflower, corn, 
olive, soybean, and sesame oils were kindly donated by Croda (UK). Stearyl alcohol, buriti oil, 
wheat germ oil, hazelnut oil, grape seed oil, sunflower oil and isopropyl palmitate were kindly 
donated by Mapric (Brazil). Propylene glycol dicaprylate/dicaprate (Miglyol® 840) and Capric 
and caprylic acid esters (Miglyol® 812) were kindly donated by IOI Oleo Chemical. 
Phosphatidylcholine from soybean (Lipoid® S100) were kindly donated by LIPOID GMBH. 
Methanol and Acentonitrile HPLC grade were purchased from JTBaker. Purifed water was 
prepared using Milli-Q quality (Millipore, USA). All other reagents were at least analytical grade 
and were used without further purification. 
 
Selection of Liquid Lipids 
The equipment, Crystal 16TM (Crystal Pharmatech Inc., USA), was used to determine 
the liquid lipid that solubilized the highest quantity of NFOH. For the test, 5.0 mg of NFOH was 
added to 1.0 g of liquid lipid in a 2.0 mL vial. The parameters used were: 700 rpm, at 80°C for 
one h, with a heating and cooling ramp of 2.7°C/min. The second step for selection was 
performed as follows: 200 mg of Lipoid® S100 were added to the previous vials, under the same 
conditions described above. According to the equipment manufacuturer’s guidelines, the lipids 
presenting turbidity were excluded from the experiment. In the third step, the optimized 
proportion of Lipoid® S100: liquid lipid was investigated. Therefore, the selected liquid lipids and 
the suitable proportion of Lipoid®: liquid lipid were tested using different concentrations of NFOH 
(1.0-12.0 mg/g of lipid). The system with the highest concentration of the solubilization NFOH 
was selected. 
The quantification of NFOH was performed using spectrophotometry UV/vis Evolution 
series 201 (Thermo Fisher Scientific, Waltham, MA, USA) operated at 370 nm. The sample was 
prepared with the addition of NFOH in excess to the liquid lipid and placed in a magnetic stirrer 
at 80°C. After 1 h, aliquots were filtered through a PVDF membrane of 0.22-µm pore size and 
diluted in acetonitrile.   
Selection of Solid Lipid 
NFOH solubility in solid lipids was evaluated according to Kasongo et al [21]. NFOH 
was added to the solid lipid in a concentration of 0.001% (w/w); this preparation was heated 
10°C above the melting point of each lipid, under constant shaking. Aliquots were taken and 
observed by an optical microscope Olympus CK2 (Japan); the NFOH concentration was 
adjusted until crystals were observed.  
Additionally, drug solubility and crystallization behavior in solid lipids were carried out 
by using differential scanning calorimetry (DSC), according to Monteiro et al [12]. The NFOH, 
solid lipids, 1:1 physical mixtures (PM) and the mixtures of selected lipids thermal behavior were 
characterized in a DSC 4,000 Perkin Elmer cell (Perkin Elmer Corp., Norwalk, CT, USA), under 
a dynamic N2 atmosphere (50 mL/min), using a sealed aluminum pan with about 2.0 mg of 
samples. DSC curves were obtained at a heating rate of 10°C/min, and the temperature ranged 
from 25 to 290°C. An empty sealed pan was used as a reference. 
The onset temperature, maximum peak in the melting range (Tpeak) and melting 
enthalpy (∆Hm) were calculated using the software provided by PerkinElmer. The crystallinity 
indices (CI) of NFOH were calculated in percentage according to the following Equation (1) 
[22,23], 
𝐶𝐼 (%) =  
∆𝐻 𝑁𝐹𝑂𝐻 𝑃𝑀 ∗𝐷
∆𝐻 𝑁𝐹𝑂𝐻 100%
 ∗ 100  Equation (1) 
where ΔHNFOH PM is the enthalpy of fusion (J.mg-1) of NFOH in the binary physical 
mixture of NFOH and solid lipid, ΔHNFOH 100% is the enthalpy of fusion (J.mg-1) of pure drug. D is 
the dilution of NFOH in the solid lipids, in this case, 1:1, D=2. 
 
Preparation of NLC-NFOH 
A total of 50.0g of the formulation was prepared using the selected liquid lipid, solid 
lipids and poloxamer 188. The oil and aqueous phases were heated to 80°C using RTC basic 
IKA® magnetic stirrer at 300 rpm until complete dissolution. Then, the aqueous phase was 
dispersed in the oil phase, and mixed by a mechanical homogenizer at 8000 rpm (Ultraturrax, 
IKA) for 5 min. The coarse emulsion was passed through a high-pressure homogenizer using 
Nano DeBEE® (BEE International, Inc. USA) using five successive cycles at 600 bar [12]. 
 
Z-average, polydispersity index and potential zeta analysis 
The z-average of the nanostructured lipid carriers was assessed by photon correlation 
spectroscopy (PCS) using Zetasizer ZS90 (Malvern Instruments, Malvern, UK) at 25°C and a 
90° detection angle. The equipment was also used to measure the zeta potential (ZP). ZP 
measurements were carried out in purified water with a conductivity adjusted to 50 µS.cm -1 by 
adding NaCl 0.2% (w/v), to avoid ZP fluctuations caused by the difference in conductivity (n = 
3). The pH of formulations was determined using a pH measurement system (MP 220, Mettler 
Toledo® Inc, Columbus, OH, US) previously calibrated at 20°C. The particle size of the 
optimized NLC-NFOH was also determined by laser-based particle size analyzer CILAS 1090 
(Orleans, France) in aqueous medium.  
 
Determination of encapsulation efficiency (EE%) and drug 
loading (DL%) 
NLC-NFOH was ultrafiltrated using Amicon Ultra-0.5 mL Ultracel-10 membrane 50 
kDa centrifugal filters (Millipore Merck, USA). Then, the filter was centrifuged at 590 g for 30 
min. The supernatant and the filtrate were suitably diluted and analyzed for NFOH in 
spectrophotometry method as described earlier. The EE% and DL% were determined using the 
equation (2) and equation (3), respectively. 
𝐸𝐸% =  
𝑊𝑡𝑜𝑡𝑎𝑙−𝑊𝑓𝑟𝑒𝑒
𝑊𝑡𝑜𝑡𝑎𝑙 
 𝑥 100  Equation (2) 
 
𝐷𝐿% =  
𝑊𝑡𝑜𝑡𝑎𝑙−𝑊𝑓𝑟𝑒𝑒
𝑊𝑙𝑖𝑝𝑖𝑑
 𝑥 100  Equation (3) 
 
Where Wtotal is weight of initial NFOH added, W free is the weight of free drug detected 
in the filtrate after centrifugation and W lipid is the weight of lipid at the formulation. 
 
NLC development and optimization 
An extreme vertex experiment, with five-factor, grade 3, two-level D-Optimal mixture 
statistical design was used to evaluate the lipids and surfactant concentration effects on NLC z-
average using Minitab® 18 software (State College PA, USA).  To design the mathematical 
model the following restrictions were used: 2.0% to 5.0% w/w of Gelucire® 50/13 concentration 
and ≤ 8.0% w/w of Precirol® ATO 5 + Miglyol® 840 concentration. The independent variables 
are shown in Table 1 and the dependent variable (response) was z-average. A total of 45 
experiments were designed by Minitab 18 (Table S2).  
 




Gelucire® 50/13 (Gel) 2.0 5.0 
Precirol® ATO 5 (Prec) 0.0 7.0 
Miglyol® 840 (Mig) 2.0 9.0 
Poloxamer® 188 (Pol) 0.0 3.0 
Water 86.0 90.0 
 
 
Determination of NFOH in plasma  
The Ethics Committee approved the animal experiment protocol (protocol 
n°1155/2019). NLC-NFOH (2.8 mg/kg) was administered to one healthy male Wistar rat (341g) 
by gavage. After 5 h blood from the carotid vein was collected. A blood sample was collected to 
heparin tubes (10 µl, 500 IU/mL). Plasma samples were obtained immediately by centrifuging at 
8000 rpm for 10 min, and stored at -20°C until further analysis by HPLC [24]. Plasma samples 
(200 µL) were mixed with acetonitrile (200 µL), to precipitate proteins, then centrifuged at 10000 
rpm for 10 min. The supernatant was transferred to a vial insert and analyzed in HPLC. 
The quantification of NFOH in plasma was performed according to Monteiro et al [25]. 
The Shimadzu HPLC-UV system consisted of a CBM-20A controller, LC-20AT-pump, SPD-20A 
detector, and SIL-20AC sampler LC Solution software (version 1.25SP4) was applied for data 
collecting and processing.   The mobile phase consisted of acetonitrile: water (20:80) at a flow 
rate of 1.2 mL/min and the UV detector at 265 nm. The volume of injection was 20 μl. The 
method was linear (r= 0.9997) in the concentration range of 10 - 0.1 µg/mL.  
 
Result  
Selection of liquid lipid 
 
Crystal 16TM detects the turbidity of the solution through a laser that passes through 
the vials. The clearer the solution, the higher the solubility of the drug in the oil. In the first 
screening, none of the 23 oils tested showed a 100% clear solution. In the second screening, 
Lipoid® S100, a solubilizer agent, was added to improve the solubility of NFOH in these oils. 
Buriti oil, grape seed oil, Miglyol® 840, Capmul® MCM, Captex® 300 and Miglyol® 812 showed 
100% clear solution. The interaction of Lipoid® S100 and the oils helped solubilize the NFOH. 
The proportion of Lipoid® S100 and liquid lipid was optimized to 1:9. 
To determine if the selected liquid lipids were able to solubilize more than 5.0 mg/g of 
drug substance, different vials with variable amounts of NFOH (6.0 to 12.0 mg/g) were 
evaluated in a Crystal 16TM instrument.  The maximum amount of NFOH solubilized in Miglyol® 
840 was 8.0 mg/g. This solubilized concentration remains after cooling the solution. For the 
Miglyol® 812, the maximum quantity of solubilized NFOH was 6.0 mg/g. The NFOH 
quantification by spectroscopy in Miglyol® 840 and Miglyol® 812 were 14.0 mg/g and 10.2 mg/g, 
respectively. Due to the superior NFOH solubility, Miglyol® 840 was chosen as the liquid lipid for 
the preparation of nanostructure lipid carrier.  
 
Selection of solid lipids 
Eight solid lipids were analyzed by microscopy to evaluate the solubility of NFOH. 
NFOH was soluble in all the lipids tested at 1.0 mg/g, except for Gelucire 44/10. Microscopy 
revealed Gelucire® 50/13 was the only solid lipid to solubilize 2.0 mg/g of NFOH. Figure 2 
showed the microscopy of NFOH in Gelucire® 50/13.  
 
 
Figure 2. Optical micrographs (x10) of (A) NFOH; (B) Gelucire® 50/13; (C) Gelucire® 50/13 
and NFOH (2.0mg/g) and (D) Gelucire® 50/13 and NFOH (10mg/g).  
 
The melting enthalpy obtained from DSC data and the Cristalinity index (CI) of NFOH 
and solid lipids mixtures were used to select the best solid lipid (Table S1). The pure drug 
presents ∆HNFOH 12.8 (kJ/mg); the greater the reduction in CI, the better the ability of the lipid to 
solubilize the drug [12]. Gelucire® 50/13 mixture (Figure 3) resulted in the lowest CI of NFOH, of 
63.5 which is in consonance with the microscopic screening. Thus, it was the chosen SL for the 
preparation of nanostructure lipid carrier. Precirol® ATO 5, presenting the second-best CI 




Figure 3. DSC curves of hydroxymethylnitrofurazone (NFOH), Gelucire® 50/13, and NFOH and 
Gelucire® 50/13 – physical mixture (PM) obtained at  = 10°C/min. 
 
NLC development and optimization 
The restrictions were determined in a preliminary study. Gelation was observed in a 
mixture composed of Precirol® ATO 5 and Miglyol® 840 at the ratio of 4:1. However, when 
Gelucire® 50/13 was added to this mixture, the gelation was not observed (data not shown). The 
addition of surfactants can also avoid the gelation [26]. Thus, Gelucire® 50/13 was added to all 
formulations of statistical design. The Z-average ranged from 100.9 nm to 294.0 nm and PdI 
from 0.12 to 0.66 (Table S2). 
The R-square (R2), adjusted-R2 (adj-R2) and predicted R2 (pred-R2) were 89.54%, 
87.21% and 83.67%, respectively. The normal probability plot of the residuals was 
approximately linear revealing a normally distributed behavior (data not shown). The linear 
model was significant (p<0.05; α=0.05) (Table S3). The mathematical model (Equation 4) 
showed the influence of independent variables for the z-average. The interaction of Gelucire® 
50/13+Precirol® ATO 5, Gelucire® 50/13+Miglyol® 840, and   Precirol® ATO 5 + Poloxamer® 188 
resulted in a synergy that helped decrease the z-average. Interestingly, the mix of the three 
compounds, Gelucire® 50/13+Precirol® ATO 5+Poloxamer® 188, showed the opposite 
response, significantly increasing the z-average. Table 2 shows the optimized formulations with 
a z-average less than 200 nm (monomodal distribution), which verified the validity of the 
mathematical model. The contour plots are presented in Figure 4. The EE% of F1 and F2 were 
58.8% and 61.7%, respectively and DL% were 21,6% and 34,5%, respectively.  
 
𝑍 − 𝑎𝑣𝑒𝑟𝑎𝑔𝑒 = +3210 ∗ 𝐺𝑒𝑙 + 4970 ∗ 𝑃𝑟𝑒𝑐 + 2216 ∗ 𝑀𝑖𝑔 + 1124 ∗ 𝑃𝑜𝑙 − 8.4 ∗ 𝑊𝑎𝑡𝑒𝑟 − 98856 ∗ 𝐺𝑒𝑙 ∗
𝑃𝑟𝑒𝑐 − 60703 ∗ 𝐺𝑒𝑙 ∗ 𝑀𝑖𝑔 − 98279 ∗ 𝑃𝑟𝑒𝑐 ∗ 𝑃𝑜𝑙 + 1351126 ∗ 𝐺𝑒𝑙 ∗ 𝑃𝑟𝑒𝑐 ∗ 𝑃𝑜𝑙    Equation (4) 
 
Table 2. Observed and predicted z-average, polydispersity index (PDI) and zeta potential (ZP) 






Gelucire® 50/13 4.70 2.30 
Precirol® ATO 5 2.45 3.70 
Miglyol® 840 3.00 4.00 
Poloxamer® 188 1.00 0.00 
Water 88.85 90.00 
Observed z-average (nm) ± SD 135.3 ± 2.1 198.6 ± 5.4 
Predicted z-average (nm) 134.9 198.7 
PDI ± SD 0.23 ± 0.02 0.11 ± 0.01 
ZP (mV) ± SD -13.7 ± 0.9 -13.7 ± 0.7 
pH 4.92 4.98 




Figure 4. Contour plots of the NLC-NFOH mathematical model for z-average, containing the 
following variables: Gelucire® 50/13, Precirol® ATO 5, Miglyol® 840, Poloxamer® 188, and 
Water 
F2 particle size was also determined using a laser-based particle size analyzer. The 
diameter 50%, d(50), was 170 nm and the media size was 220 nm (Figure S1).  
 
Determination of NFOH in plasma  
The NFOH was successfully detected in animal after oral administration of F2. The 
time of retention of NFOH was 2.6 minutes for NFOH solution and NFOH in plasma (Figure S2). 
The plasma concentration of NFOH after 5h of oral administration in rat was 0.22 µg/mL. 
 
Discussion 
The use of different tools for selecting lipids provided relevant scientific knowledge for 
the development of the NLC. Shake flask and spectrophotometry are the conventional 
approaches used to select liquid lipids [27]. However, the use of Crystal 16TM helped to screen a 
large number of liquid lipids in a short time, low amount, without the use of organic solvent. 
Microscopy is also frequently used to select solid lipids [21,28,29], but it presents some 
limitations such as  being time-consuming, presenting semi-quantitative results, and the 
experience of the analyst [12]. DSC used in this study could overcome these limitations. Thus, 
the association of these methods is substantial in saving time, material and labor. 
The first selected liquid lipid was Miglyol® 840, a diester related to medium chain 
triglycerides (propylene glycol dicaprylate / dicaprate) [30]. It has been used for developing 
formulations in oral,[31–33] ophthalmic [34,35], subcutaneous [32], dermatological [36] and 
transdermal applications [37,38]. In order to increase the solubility of NFOH in Miglyol® 840, 
Lipoid® S100 was added. Lipoid® S100 is a lecithin derived from soybeans and contains 100% 
phosphatidylcholine, one of the main naturally occurring phospholipids.  Lipoid® S100 offers a 
high transition phase temperature preventing leakage of drugs from the lipid matrix, and can 
therefore increase encapsulation efficiency [39]. In addition, when added to formulations, it can 
increase the oral bioavailability of drugs [40,41]. Despite these advantages, this component is 
highly susceptible to oxidation [42]. Therefore, it is desirable to use the smallest amount of 
Lipoid® S100 suitable to solubilized NFOH. 
Gelucire® 50/13 was selected due to the superior ability to solubilize NFOH among the 
solid lipids tested, and its lower CI. This lipid is a mixture of propylene glycol mono, di and 
triglycerides and mono and diesters of palmitic (C 16) and stearic (C 18) acids, it has a melting 
point of around 50°C, and hydrophilic-lipophilic balance (HLB) of 13. It is an amphiphilic lipid 
compound that has been used to increase the oral bioavailability of hydrophobic drugs [43–45].  
In addition, it has been used as solid lipid and surfactant in the preparation of lipid 
nanostructures [46–48]. Precirol® ATO 5 is composed of esters of palmitic (C16) and stearic 
(C18) acids, used to modify the release of drugs [49–51] and to increase oral bioavailability of 
drugs [52,53].   
Lipid polymorphism can induce gelation and instability of formulation [54,55]. Precirol® 
ATO 5 and Gelucire® 50/13 present  3 and 4 polymorphic forms, respectively [46]. The 
interaction between these two components suppressed the polymorphism. Hazza et al [48]. 
demonstrated an increase in the z-average due to the interaction between Gelucire® 50/13 and 
Precirol® ATO 5. This confirms the findings of Jeon et al. [56], which  revealed  Precirol® ATO 5 
is the main constituent of the particle walls. Gelucire® 50/13 molecules intercalate between 
Precirol® ATO 5 by Wan der Vaal forces between their lipophilic long hydrocarbon chain. When 
the concentration of Gelucire® 50/13 increases, the Gelucire® 50/13 molecules interact between 
themselves leading to a z-average increase. Thus, Gelucire® 50/13, as stabilizer, can provide 
suitable colloidal stability. Additionally, it can slow down the expulsion of the encapsulated drug 
[46]. 
In the present study, when Gelucire® 50/13 concentration increased from 2.0 to 5.0%, 
the NLC-NFOH z-average decreased, contrary to Jeon’s study. This can be attributed to the 
addition of Miglyol® 840 to the formulation. This liquid lipid decreased the crystallinity of solid 
lipids reducing the particle size [57]. Furthermore, Precirol® ATO 5 (HLB = 2) may facilitate 
emulsification efficiency when combining with Miglyol® 840, leading to a lower particle size [35].  
The use of a design space allowed for a systematic rational approach in the 
development of NLC-NFOH. The knowledge of the attributes that influence the z-average of the 
formulation provided an optimized NLC. Thus, the mathematical model demonstrated the 
predicted z-average similar to the observed values (Table 2). Two preparations were selected to 
verify the model: F1 and F2. Gelucire® 50/13 (2.30 to 4.70% w/w) acted as solid lipid and also 
as a stabilizer for the formulation. The F2, without Poloxamer® 188, presented stability of three 
months (Table S4). Poloxamer was intended to act as gelation inhibitor in this system; however, 
the applied concentration of Gelucire® 50/13 seemed to be enough for this proposal. Therefore, 
the preparation F2 was chosen for the in vivo preliminary assay.  
The analysis of plasma concentration of NFOH using Wistar rats (approx. 250g) was 
also performed and determined by Serafin et al. [58]; the authors found  a plasma concentration 
of 0.25 mg/mL at 5h, which is similar to the concentration determined in our study (0.22 mg/mL) 
using NLC-NFOH at 2.8 mg/Kg. Thus, it was possible to achieve a similar plasma concentration 
using an almost 100-fold lower dose and despite the DL% below 40%. These preliminary results 
indicate that NLC might improve oral absorption of NFOH. Some studies have shown retard 
and/or sustained in vitro release from drugs in NLC [14,41,60]. Fathi et al. [60] and Kar et al. 
[14] showed an initial burst in the release study; this can be attributed to the entrapped drug on 
the surface of the nanoparticle. But both studies showed a sustained released, attributed, 
probably the lipophilic nature of the drug and the lipid formulation. Lipid-based formulations can 
enhance the solubility and bioavailability of poorly soluble drugs by keeping drugs solubilized in 
the gastrointestinal tract, enhance mucosal adhesion, and/or gradually releasing drug molecules 
from the lipid matrix into the blood. In addition, these formulations can improve therapeutic 
profiles compared to the free drug due to the protection from chemical and enzymatic 
degradation of the drug [61,62]. Therefore, our group is encouraged to continue researching the 
influence of NLC aiming at high bioavailability of NFOH. 
 
Conclusion 
A rational approach allowed to successfully develop the first stable NLC-NFOH. The 
D-Optimal mixture statistical design was effectively used to optimize the formulation. Besides, 
within the design space, it was possible to have a better understanding of the attributes that 
influence the z-average of the formulation. Gelucire® 50/13 decreased the z-average, while the 
addition of Precirol® ATO 5 increased the z-average. Additionally, the preliminary experiment of 
NLC-NFOH in rats demonstrated the presence of NFOH in plasma at a lower concentration of 
oral administration, compared to other studies. Under these promising results, we consider the 
NLC-NFOH as a potential candidate of oral medicine to treat leishmaniasis. 
 
Acknowledgements 
The authors thank Jim Hesson (James Joseph Hesson) of Academic English 
Solutions for the English language editing services of this manuscript 
(http://www.AcademicEnglishSolutions.com), Dafra Technologies Instrumentacao Analitica e 
Cientifica Ltda for giving in to the use of Crystal 16TM (Crystal Pharmatech Inc., USA) 
equipment, CAPES (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior) and 
CNPq (Conselho Nacional de Desenvolvimento Científico e Tecnológico).  
 
Funding sources 
This work was supported by “Fundação de Amparo à Pesquisa do Estado de 
São Paulo (FAPESP)” [grant number 2017/08332-3]  
References 
[1] A. de Souza, D.S.S. Marins, S.L. Mathias, L.M. Monteiro, M.N. Yukuyama, C.B. Scarim, 
R. Löbenberg, N.A. Bou-Chacra, Promising nanotherapy in treating leishmaniasis, Int. J. 
Pharm. 547 (2018) 421–431. doi:10.1016/j.ijpharm.2018.06.018. 
[2] World Health Organization, Investing to overcome the global impact of neglected tropical 
diseases: third report on neglectes diseases 2015, (2015) 1–211. 
http://www.who.int/neglected_diseases. 
[3] F. Marquele-Oliveira, E.C. Torres, H. da S. Barud, K.F. Zoccal, L.H. Faccioli, J.I. Hori, 
A.A. Berretta, Physicochemical characterization by AFM, FT-IR and DSC and biological 
assays of a promising antileishmania delivery system loaded with a natural Brazilian 
product, J. Pharm. Biomed. Anal. 123 (2016) 195–204. doi:10.1016/j.jpba.2016.01.045. 
[4] World Health Organization, Control of the leishmaniases: report of a meeting of the 
WHO expert committee on the control of leishmaniases., World Health Organization, 
Geneva, 2010. https://www.cabdirect.org/cabdirect/abstract/20123045323 (accessed 
May 27, 2019). 
[5] M.C. Chung, R.V. Carvalho Güido, T. Favarato Martinelli, M. Ferreira Gonçalves, M. 
Carneiro Polli, K.C. Alves Botelho, E. Aparecida Varanda, W. Colli, M.T.M. Miranda, E. 
Igne Ferreira, Synthesis and in vitro evaluation of potential antichagasic 
hydroxymethylnitrofurazone (NFOH-121): A new nitrofurazone prodrug, Bioorganic Med. 
Chem. 11 (2003) 4779–4783. doi:10.1016/j.bmc.2003.07.004. 
[6] L.M. Monteiro, R. Löbenberg, E.I. Ferreira, P.C. Cotrim, E. Kanashiro, M. Rocha, M.C. 
Chung, N. Bou-Chacra, Targeting Leishmania amazonensis amastigotes through 
macrophage internalisation of a hydroxymethylnitrofurazone nanostructured polymeric 
system, Int. J. Antimicrob. Agents. 50 (2017) 88–92. 
doi:10.1016/j.ijantimicag.2017.01.033. 
[7] A. Beloqui, M.Á. Solinís, A. Rodríguez-Gascón, A.J. Almeida, V. Préat, Nanostructured 
lipid carriers: Promising drug delivery systems for future clinics, Nanomedicine 
Nanotechnology, Biol. Med. 12 (2016) 143–161. doi:10.1016/j.nano.2015.09.004. 
[8] L. Liu, C. Jiang, Drug Delivery Strategies Based on Nanotechnology for Cancer 
Immunotherapy, Curr. Org. Chem. 21 (2017) 34–44. 
doi:10.2174/1385272820666160511121. 
[9] B. Zulfiqar, A. Mahroo, K. Nasir, R. Farooq, N. Jalal, M.U. Rashid, K. Asghar, 
Nanomedicine and cancer immunotherapy: focus on indoleamine 2,3-dioxygenase 
inhibitors, Onco. Targets. Ther. 10 (2017) 463–476. doi:10.2147/OTT.S119362. 
[10] N. Poonia, R. Kharb, V. Lather, D. Pandita, Nanostructured lipid carriers: versatile oral 
delivery vehicle, Futur. Sci. OA. 2 (2016) FSO135. doi:10.4155/fsoa-2016-0030. 
[11] N. Naseri, H. Valizadeh, P. Zakeri-milani, Solid Lipid Nanoparticles and Nanostructured 
Lipid Carriers : Structure , Preparation and Application, Tabriz Univ. Med. Sci. 5 (2015) 
305–313. doi:10.15171/apb.2015.043. 
[12] L.M. Monteiro, R. Löbenberg, P.C. Cotrim, G. Lima, B. De Araujo, N. Bou-chacra, 
Buparvaquone Nanostructured Lipid Carrier : Development of an Affordable Delivery 
System for the Treatment of Leishmaniases, Biomed Res. Int. 2017 (2017) 1–11. 
doi:10.1155/2017/9781603. 
[13] L.M. Monteiro, R. Löbenberg, N. Fotaki, G.L.B. de Araújo, P.C. Cotrim, N. Bou-Chacra, 
Co-delivery of buparvaquone and polymyxin B in a nanostructured lipid carrier for 
leishmaniasis treatment, J. Glob. Antimicrob. Resist. 18 (2019) 279–283. 
doi:10.1016/j.jgar.2019.06.006. 
[14] N. Kar, S. Chakraborty, A.K. De, S. Ghosh, T. Bera, Development and evaluation of a 
cedrol-loaded nanostructured lipid carrier system for in vitro and in vivo susceptibilities of 
wild and drug resistant Leishmania donovani amastigotes, Eur. J. Pharm. Sci. 104 
(2017) 196–211. doi:10.1016/j.ejps.2017.03.046. 
[15] J.S.L. Tan, C. Roberts, N. Billa, Pharmacokinetics and tissue distribution of an orally 
administered mucoadhesive chitosan-coated amphotericin B-Loaded nanostructured 
lipid carrier (NLC) in rats, J. Biomater. Sci. Polym. Ed. 31 (2020) 141–154. 
doi:10.1080/09205063.2019.1680926. 
[16] L.M. Negi, M. Jaggi, S. Talegaonkar, Development of protocol for screening the 
formulation components and the assessment of common quality problems of nano-
structured lipid carriers, Int. J. Pharm. 461 (2014) 403–410. 
doi:10.1016/J.IJPHARM.2013.12.006. 
[17] F. Tamjidi, M. Shahedi, J. Varshosaz, A. Nasirpour, Nanostructured lipid carriers (NLC): 
A potential delivery system for bioactive food molecules, Innov. Food Sci. Emerg. 
Technol. 19 (2013) 29–43. doi:10.1016/J.IFSET.2013.03.002. 
[18] M.N. Yukuyama, E.T.M. Kato, G.L.B. de Araujo, R. Löbenberg, L.M. Monteiro, F.R. 
Lourenço, N.A. Bou-Chacra, Olive oil nanoemulsion preparation using high-pressure 
homogenization and d-phase emulsification – A design space approach, J. Drug Deliv. 
Sci. Technol. 49 (2019) 622–631. doi:10.1016/j.jddst.2018.12.029. 
[19] K. Jain, S. Sood, K. Gowthamarajan, Optimization of artemether-loaded NLC for 
intranasal delivery using central composite design, Drug Deliv. 22 (2015) 940–954. 
doi:10.3109/10717544.2014.885999. 
[20] G.R. Valicherla, K.M. Dave, A.A. Syed, M. Riyazuddin, A.P. Gupta, A. Singh, 
Wahajuddin, K. Mitra, D. Datta, J.R. Gayen, Formulation optimization of Docetaxel 
loaded self-emulsifying drug delivery system to enhance bioavailability and anti-tumor 
activity, Sci. Rep. 6 (2016) 26895. doi:10.1038/srep26895. 
[21] W.K. Kasongo, J. Pardeike, R.H.. Müller, R.B. Walker, Selection and Characterization of 
Suitable Lipid Excipients for use in the Manufacture of Didanosine-Loaded Solid Lipid 
Nanoparticles and Nanostructured Lipid Carriers, J. Pharm. Sci. 100 (2011) 5185–5196. 
[22] E.B. Souto, R.H. Müller, SLN and NLC for topical delivery of ketoconazole, J. 
Microencapsul. 22 (2005) 501–510. doi:10.1080/02652040500162436. 
[23] C. Freitas, R.H. Müller, Correlation between long-term stability of solid lipid nanoparticles 
(SLNTM) and crystallinity of the lipid phase, Eur. J. Pharm. Biopharm. 47 (1999) 125–132. 
doi:10.1016/S0939-6411(98)00074-5. 
[24] E. Kimura, C.A. Bersani-Amado, L.S. Sudo, S.R.J. Santos, S. Oga, Pharmacokinetic 
profile of piroxicam β-cyclodextrin, in rat plasma and lymph, Gen. Pharmacol. 28 (1997) 
695–698. doi:10.1016/S0306-3623(96)00362-X. 
[25] L.M. Monteiro, G.D. Tavares, E.I. Ferreira, V.O. Consiglieri, N.A. Bou-Chacra, R. 
L??benberg, Reverse phase high-performance liquid chromatography for quantification 
of hydroxymethylnitrofurazone in polymeric nanoparticles, Brazilian J. Pharm. Sci. 51 
(2015) 561–568. doi:10.1590/S1984-82502015000300008. 
[26] E.B. Souto, A.J. Almeida, R.H. Müller, Lipid nanoparticles (SLN®, NLC®) for cutaneous 
drug delivery: Structure, protection and skin effects, J. Biomed. Nanotechnol. 3 (2007) 
317–331. doi:10.1166/jbn.2007.049. 
[27] S.P. Balguri, G.R. Adelli, S. Majumdar, Topical ophthalmic lipid nanoparticle formulations 
(SLN, NLC) of indomethacin for delivery to the posterior segment ocular tissues, Eur. J. 
Pharm. Biopharm. 109 (2016) 224–235. doi:10.1016/J.EJPB.2016.10.015. 
[28] R.H. Müller, S. Gohla, C.M. Keck, State of the art of nanocrystals - Special features, 
production, nanotoxicology aspects and intracellular delivery, Eur. J. Pharm. Biopharm. 
78 (2011) 1–9. doi:10.1016/j.ejpb.2011.01.007. 
[29] A. Patil-Gadhe, V. Pokharkar, Pulmonary targeting potential of rosuvastatin loaded 
nanostructured lipid carrier: Optimization by factorial design, Int. J. Pharm. 501 (2016) 
199–210. doi:10.1016/j.ijpharm.2016.01.080. 
[30] E.T. Cole, D. Cadé, H. Benameur, Challenges and opportunities in the encapsulation of 
liquid and semi-solid formulations into capsules for oral administration, Adv. Drug Deliv. 
Rev. 60 (2008) 747–756. doi:10.1016/j.addr.2007.09.009. 
[31] D. Sakloetsakun, S. Dünnhaupt, J. Barthelmes, G. Perera, A. Bernkop-Schnürch, 
Combining two technologies: Multifunctional polymers and self-nanoemulsifying drug 
delivery system (SNEDDS) for oral insulin administration, Int. J. Biol. Macromol. 61 
(2013) 363–372. doi:10.1016/J.IJBIOMAC.2013.08.002. 
[32] S.S. Salunkhe, N.M. Bhatia, M.S. Bhatia, Implications of formulation design on lipid-
based nanostructured carrier system for drug delivery to brain, Drug Deliv. 23 (2016) 
1306–1316. doi:10.3109/10717544.2014.943337. 
[33] Y. Wang, J. Sun, T. Zhang, H. Liu, F. He, Z. He, Enhanced oral bioavailability of 
tacrolimus in rats by self- microemulsifying drug delivery systems, Drug Dev. Ind. Pharm. 
37 (2011) 1225–1230. doi:10.3109/03639045.2011.565774. 
[34] J. Shen, Y. Wang, Q. Ping, Y. Xiao, X. Huang, Mucoadhesive effect of thiolated PEG 
stearate and its modified NLC for ocular drug delivery, J. Control. Release. 137 (2009) 
217–223. doi:10.1016/j.jconrel.2009.04.021. 
[35] J. Shen, M. Sun, Q. Ping, Z. Ying, W. Liu, Incorporation of liquid lipid in lipid 
nanoparticles for ocular drug delivery enhancement, Nanotechnology. 21 (2010) 025101. 
doi:10.1088/0957-4484/21/2/025101. 
[36] M. Mahjour, B.E. Mauser, Z.A. Rashidbaigi, M.B. Fawzi, Effects of propylene glycol 
diesters of caprylic and capric acids (Miglyol® 840) and ethanol binary systems on in 
vitro skin permeation of drugs, Int. J. Pharm. 95 (1993) 161–169. doi:10.1016/0378-
5173(93)90403-3. 
[37] Y. Zhang, M.P. Sadgrove, R.J. Mumper, M. Jay, Transdermal prodrug delivery for 
radionuclide decorporation: Nonaqueous gel formulation development and in vitro and in 
vivo assessment, Drug Dev. Res. 74 (2013) 322–331. doi:10.1002/ddr.21082. 
[38] Y. Zhang, M.P. Sadgrove, K. Sueda, Y.-T. Yang, E.K. Pacyniak, J.R. Kagel, B.A. Braun, 
W.C. Zamboni, R.J. Mumper, M. Jay, Nonaqueous Gel for the Transdermal Delivery of a 
DTPA Penta-ethyl Ester Prodrug, AAPS J. 15 (2013) 523–532. doi:10.1208/s12248-013-
9459-5. 
[39] X. Li, R.H. Muller, C.M. Keck, N.A. Bou-Chacra, Mucoadhesive dexamethasone acetate-
polymyxin B sulfate cationic ocular nanoemulsion - Novel combinatorial formulation 
concept, Pharmazie. 71 (2016) 327–333. doi:10.1691/ph.2016.5190. 
[40] X. Zhou, X. Zhang, Y. Ye, T. Zhang, H. Wang, Z. Ma, B. Wu, Nanostructured lipid 
carriers used for oral delivery of oridonin: An effect of ligand modification on absorption, 
Int. J. Pharm. 479 (2015) 391–398. doi:10.1016/J.IJPHARM.2014.12.068. 
[41] N. Jawahar, P.K. Hingarh, R. Arun, J. Selvaraj, A. Anbarasan, S. S, N. G, Enhanced oral 
bioavailability of an antipsychotic drug through nanostructured lipid carriers, Int. J. Biol. 
Macromol. 110 (2018) 269–275. 
https://www.sciencedirect.com/science/article/pii/S0141813017341235 (accessed March 
19, 2019). 
[42] H.-H. Jin, Q. Lu, J.-G. Jiang, Curcumin liposomes prepared with milk fat globule 
membrane phospholipids and soybean lecithin, J. Dairy Sci. 99 (2016) 1780–1790. 
doi:10.3168/JDS.2015-10391. 
[43] J. de Oliveira Eloy, J. Saraiva, S. de Albuquerque, J.M. Marchetti, Solid Dispersion of 
Ursolic Acid in Gelucire 50/13: a Strategy to Enhance Drug Release and Trypanocidal 
Activity, AAPS PharmSciTech. 13 (2012) 1436–1445. doi:10.1208/s12249-012-9868-2. 
[44] C.J. Jiménez de los Santos, J.I. Pérez-Martínez, M.E. Gómez-Pantoja, J.R. Moyano, 
Enhancement of albendazole dissolution properties using solid dispersions with Gelucire 
50/13 and PEG 15000, J. Drug Deliv. Sci. Technol. 42 (2017) 261–272. 
doi:10.1016/j.jddst.2017.03.030. 
[45] M. El-Badry, G. Fetih, M. Fathy, Improvement of solubility and dissolution rate of 
indomethacin by solid dispersions in Gelucire 50/13 and PEG4000, Saudi Pharm. J. 17 
(2009) 217–225. doi:10.1016/j.jsps.2009.08.006. 
[46] A.A. Date, N. Vador, A. Jagtap, M.S. Nagarsenker, Lipid nanocarriers (GeluPearl) 
containing amphhiphilic lipid Gelucire 50/13 as a novel stabilizer: fabrication, 
characterization and evaluation for oral drug delivery, Nanotechnology. 22 (2011). 
doi:10.1088/0957-4484/22/27/275102. 
[47] N.K. Garg, R.K. Tyagi, B. Singh, G. Sharma, P. Nirbhavane, V. Kushwah, S. Jain, O.P. 
Katare, Nanostructured lipid carrier mediates effective delivery of methotrexate to induce 
apoptosis of rheumatoid arthritis via NF-κB and FOXO1, Int. J. Pharm. 499 (2016) 301–
320. doi:10.1016/j.ijpharm.2015.12.061. 
[48] H.A. Hazzah, R.M. Farid, M.M.A. Nasra, W.A. Hazzah, M.A. El-Massik, O.Y. Abdallah, 
Gelucire-Based Nanoparticles for Curcumin Targeting to Oral Mucosa: Preparation, 
Characterization, and Antimicrobial Activity Assessment, J. Pharm. Sci. 104 (2015) 
3913–3924. doi:10.1002/jps.24590. 
[49] Y. Agrawal, K.C. Petkar, K.K. Sawant, Development, evaluation and clinical studies of 
Acitretin loaded nanostructured lipid carriers for topical treatment of psoriasis, Int. J. 
Pharm. 401 (2010) 93–102. doi:10.1016/J.IJPHARM.2010.09.007. 
[50] V. Jannin, E. Pochard, O. Chambin, Influence of poloxamers on the dissolution 
performance and stability of controlled-release formulations containing Precirol® ATO 5, 
Int. J. Pharm. 309 (2006) 6–15. doi:10.1016/J.IJPHARM.2005.10.042. 
[51] X. Zhao, Q. Chen, W. Liu, Y. Li, H. Tang, X. Liu, X. Yang, Codelivery of doxorubicin and 
curcumin with lipid nanoparticles results in improved efficacy of chemotherapy in liver 
cancer., Int. J. Nanomedicine. 10 (2015) 257–70. doi:10.2147/IJN.S73322. 
[52] W. Li, T. Zhang, Y. Ye, X. Zhang, B. Wu, Enhanced bioavailability of tripterine through 
lipid nanoparticles using broccoli-derived lipids as a carrier material, Int. J. Pharm. 495 
(2015) 948–955. doi:10.1016/J.IJPHARM.2015.10.011. 
[53] P. Ramalingam, Y.T. Ko, Improved oral delivery of resveratrol from N-trimethyl chitosan-
g-palmitic acid surface-modified solid lipid nanoparticles, Colloids Surfaces B 
Biointerfaces. 139 (2016) 52–61. doi:10.1016/J.COLSURFB.2015.11.050. 
[54] M. Sznitowska, E. Wolska, H. Baranska, K. Cal, J. Pietkiewicz, The effect of a lipid 
composition and a surfactant on the characteristics of the solid lipid microspheres and 
nanospheres (SLM and SLN), Eur. J. Pharm. Biopharm. 110 (2017) 24–30. 
doi:10.1016/j.ejpb.2016.10.023. 
[55] T. Helgason, T.S. Awad, K. Kristbergsson, D.J. McClements, J. Weiss, Influence of 
polymorphic transformations on gelation of tripalmitin solid lipid nanoparticle 
suspensions, JAOCS, J. Am. Oil Chem. Soc. 85 (2008) 501–511. doi:10.1007/s11746-
008-1219-9. 
[56] H.S. Jeon, J.E. Seo, M.S. Kim, M.H. Kang, D.H. Oh, S.O. Jeon, S.H. Jeong, Y.W. Choi, 
S. Lee, A retinyl palmitate-loaded solid lipid nanoparticle system: Effect of surface 
modification with dicetyl phosphate on skin permeation in vitro and anti-wrinkle effect in 
vivo, Int. J. Pharm. 452 (2013) 311–320. doi:10.1016/j.ijpharm.2013.05.023. 
[57] E.B. Souto, S.A. Wissing, C.M. Barbosa, R.H. Müller, Development of a controlled 
release formulation based on SLN and NLC for topical clotrimazole delivery, Int. J. 
Pharm. 278 (2004) 71–77. doi:10.1016/j.ijpharm.2004.02.032. 
[58] E.O.P. Serafim, A.T. De Albuquerque E Silva, A. De Haro Moreno, E. De Oliveira Vizioli, 
E.I. Ferreira, R.G. Peccinini, M.L. Ribeiro, M.C. Chung, Pharmacokinetics of 
hydroxymethylnitrofurazone, a promising new prodrug for chagas’ disease treatment, 
Antimicrob. Agents Chemother. 57 (2013) 6106–6109. doi:10.1128/AAC.02522-12. 
[59] H. Shete, S. Chatterjee, A. De, V. Patravale, Long chain lipid based tamoxifen NLC. Part 
II: Pharmacokinetic, biodistribution and in vitro anticancer efficacy studies, Int. J. Pharm. 
454 (2013) 584–592. doi:10.1016/j.ijpharm.2013.03.036. 
[60] H.A. Fathi, A. Allam, M. Elsabahy, G. Fetih, M. El-Badry, Nanostructured lipid carriers for 
improved oral delivery and prolonged antihyperlipidemic effect of simvastatin, Colloids 
Surfaces B Biointerfaces. 162 (2018) 236–245. doi:10.1016/j.colsurfb.2017.11.064. 
[61] P. Severino, T. Andreani, A.S. Macedo, J.F. Fangueiro, M.H.A. Santana, A.M. Silva, E.B. 
Souto, Current State-of-Art and New Trends on Lipid Nanoparticles (SLN and NLC) for 
Oral Drug Delivery, J. Drug Deliv. 2012 (2012). doi:10.1155/2012/750891. 
[62] S. Kollipara, R.K. Gandhi, Pharmacokinetic aspects and in vitro–in vivo correlation 
potential for lipid-based formulations, Acta Pharm. Sin. B. 4 (2014) 333–349. 
doi:10.1016/j.apsb.2014.09.001. 
 
